Merus to Participate in William Blair's Biotech Focus Conference 2021
On July 7, 2021, Merus N.V. (Nasdaq: MRUS) announced that CEO Bill Lundberg, M.D. will participate in the panel discussion titled Moving Beyond Monoclonals: The Potential of Multispecific Therapies at William Blair's Biotech Focus Conference 2021. The event is scheduled for July 14 at 11:20 a.m. ET. Investors can access the live webcast on the Company's website, with an archived presentation available for a limited time.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a panel discussion, Moving Beyond Monoclonals: The Potential of Multispecific Therapies, at William Blair's Biotech Focus Conference 2021 on Wednesday, July 14 at 11:20 a.m. ET.
The live webcast of the panel discussion will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
FAQ
What is the date and time of Merus N.V.'s CEO participation at the Biotech Focus Conference 2021?
Where can I watch the panel discussion featuring Merus N.V.'s CEO?
What is the focus of the panel discussion at the William Blair's conference?
What innovative therapies does Merus N.V. develop?
What platform will host the archived presentation from the Merus N.V. panel?
